Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysisaXess is a restorative arteriovenous.